Weight-Loss Drug Headlines: Lilly vs Novo

Rates across the world are climbing as central banks raise inflation warnings. How yesterday’s Fed decision sets up a potential rate *hike* at the bank’s June meeting, and when the recent jump in yields could finally hit the equity market. Plus, Eli Lilly’s latest trial data, Novo’s FDA approval, and the patent expiration that could shake up the weight loss drug space.  

Fast Money Disclaimer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.